As a proof‐of‐concept, we have demonstrated that rTHBS2 is effective in sensitizing HCC tumors to 5‐FU chemotherapy and in diminishing CD133 expression concomitant with enhanced tissue stiffness. Here, PROM1 is linked to hepatocellular carcinoma.